Publications by authors named "Elisa Borgonovo"
Article Synopsis
- - Edoxaban is a selective oral medication used to prevent strokes in patients with non-valvular atrial fibrillation, but it is not safe for individuals with severe liver disease.
- - Common side effects of edoxaban include elevated levels of serum bilirubin and gamma-glutamyl transpeptidase.
- - An 82-year-old man with liver cancer experienced a severe and fatal condition called vanishing bile duct syndrome shortly after starting edoxaban, marking the first documented case linking the drug to this syndrome.
Aim: The aim of this study was to investigate whether treatment with rapamycin plus vildagliptin restores β-cell function in patients with long-standing type 1 diabetes.
Methods: A phase 2, single-center, randomized, double-blind, placebo-controlled study was conducted in long-standing type 1 diabetes patients randomly assigned (1:1:1) to 4 weeks of rapamycin (group 2), 4 weeks of rapamycin plus 12 weeks of vildagliptin (group 3), or double placebo (group 1). The primary outcome was the proportion of participants with a positive response to the Mixed-Meal Tolerance Test (C-peptide at 90 minutes > 0.